Davis's Drug Guide
mavacamten
General
**REMS Drug**
Genetic Implications:
Pronunciation:
mav-a-kam-ten
Trade Name(s)
- Camzyos
Ther. Class.
heart failure agents
Pharm. Class.
temporary class
cardiac myosin inhibitorThere's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Mavacamten." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2025. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580063/all/mavacamten.
Vallerand AHA, Sanoski CAC, . Mavacamten. Davis's Drug Guide. F.A. Davis Company; 2025. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580063/all/mavacamten. Accessed November 3, 2025.
Vallerand, A. H., Sanoski, C. A., & , (2025). Mavacamten. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580063/all/mavacamten
Vallerand AHA, Sanoski CAC, . Mavacamten [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2025. [cited 2025 November 03]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580063/all/mavacamten.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - mavacamten
ID - 3580063
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - ,,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580063/all/mavacamten
PB - F.A. Davis Company
ET - 19
DB - Medicine Central
DP - Unbound Medicine
ER -
